Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 9—September 2022
Research

Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019

Yousra KherabiComments to Author , Mathilde Fréchet-Jachym, Christophe Rioux, Yazdan Yazdanpanah, Frédéric Méchaï, Valérie Pourcher, Jérôme Robert, Lorenzo Guglielmetti, and for the MDR-TB Management Group
Author affiliations: Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (Y. Kherabi, C. Rioux, Y. Yazdanpanah); Sorbonne Université, INSERM U1135, Paris (Y. Kherabi, J. Robert, L. Guglielmetti); Centre Hospitalier de Bligny, Briis-sous-Forges, France (M. Frechet-Jachym); Assistance Publique—Hopitaux de Paris, Paris (C. Rioux, Y. Yazdanpanah); INSERM U1137, IAME, Université de Paris, Paris (Y. Yazdanpanah); Universite Paris Diderot, Paris (Y. Yazdanpanah); Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Paris (F. Méchaï); Hopital Avicenne, Bobigny, France (F. Méchaï); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris (V. Pourcher); Assistance Publique Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris (J. Robert, L. Guglielmetti)

Main Article

Table 6

Serious adverse events of 298 patients affected by MDR TB, France, 2006–2019*

Characteristic Total, N = 298 TB resistance status
 p value
MDR, n = 205 Pre-XDR/XDR, n = 93
Serious adverse events
 152 (51.0)
 94 (45.9)
 58 (62.4)
 0.02
Event type
Peripheral neuropathy 82 (27.5) 50 (24.4) 32 (34.4) NS
Ototoxicity 78 (26.2) 42 (20.5) 36 (38.7) 0.001
Gastrointestinal 39 (13.1) 26 (12.7) 16 (17.2) NS
Hepatotoxicity 35 (11.7) 27 (13.2) 8 (8.6) NS
Hematologic abnormalities 29 (9.7) 17 (8.3) 12 (13.0) NS
Anemia 20 (6.7) 12 (5.9) 8 (8.6) NS
Thrombocytopenia 11 (3.7) 5 (2.4) 6 (6.5) NS
Neutropenia 6 (2.0) 4 (2.0) 2 (2.2) NS
Musculoskeletal pain 24 (8.1) 20 (9.8) 4 (4.3) NS
Tendinopathy 10 (3.4) 9 (4.4) 1 (1.1) NS
Arthralgia 15 (5.0) 12 (5.9) 3 (3.2) NS
Psychiatric 18 (6.0) 12 (5.9) 6 (6.5) NS
Renal toxicity 17 (5.7) 14 (6.8) 3 (3.2) NS
Optic neuritis 10 (3.4) 5 (2.4) 5 (5.4) NS
Hypothyroidism 9 (3.0) 6 (2.9) 3 (3.2) NS
QT prolongation 8 (2.7) 4 (2.0) 4 (4.3) NS
Other 14 (4.7) 4 (2.0) 10 (10.8) NS

*Values are no (%) except as indicated. MDR, multidrug resistant (susceptible to all fluoroquinolones); NS, not statistically significant; QT, QT interval on electrocardiogram; pre-XDR/XDR, pre–extensively drug resistant/extensively drug resistant, (resistant to >1 fluoroquinolone); TB, tuberculosis.

Main Article

Page created: July 31, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external